Written and medically reviewed by: Assoc. Prof. Cengiz Dibekoğlu, MD, General SurgeryLast updated:
CRS / HIPEC Eligibility
Performance status, histology, PCI, and a realistic chance of complete cytoreduction gate the conversation.
Eligibility starts with tumor biology and a realistic chance of clearing disease (CC-0/1). PCI helps describe burden; good performance status and controllable systemic disease matter. Declining CRS/HIPEC when futile is protective, not hopelessness.
Educational schematic. Some structures may be simplified or emphasized for clarity; not an exact anatomical depiction.
© Cengiz Dibekoğlu — illustrative; not for unauthorized use
Figure summary
Labeled on this figure: CRS · HIPEC · PCI · CC score.
Figure labels (English)
- CRS
- HIPEC
- PCI
- CC score
Who may be a candidate?
- Selected peritoneal metastases with low-to-moderate PCI and CC-0/1 likely
- Adequate fitness for prolonged major surgery
- Histologies where center protocols support CRS ± HIPEC discussion
Possible advantages
- Complete CRS can meaningfully alter natural history in the right biology
- Combines resection of involved organs only as needed for clearance
- HIPEC retained as a selective tool, not a mandatory stamp
Limits & realistic expectations
- High PCI / unresectable zones exclude many patients
- Major morbidity and long recovery
- Colorectal oxaliplatin HIPEC lacks OS benefit in PRODIGE-7
Step-by-step overview
- 1
Clarify the clinical question
What diagnosis is being confirmed and what decision follows?
- 2
Choose first-line tests
Start with the test that answers the leading question safely.
- 3
Stage if needed
Add imaging or endoscopy when results would change management.
- 4
Name limitations
No test replaces exam; false reassurance is a risk.
- 5
Link to next step
Diagnosis should point to observation, medical care, or procedure.
Key points
Diseases where CRS is more often discussed
Not every peritoneal spread is the same. In practice, CRS (± selective HIPEC) is most often discussed in these spectra — still individualized. A disease label is not a guarantee of surgery; PCI, biology, and fitness still decide.
- Selected colorectal peritoneal metastases (first: is complete cytoreduction realistic?)
- Low-grade appendiceal mucinous neoplasms and pseudomyxoma (PMP) spectrum
- Selected ovarian cancer pathways — with gynecologic oncology
- Some peritoneal mesothelioma cases — per experienced center protocols
How scoring enters the decision
PCI describes burden; CC frames the clearance goal after CRS. When burden is lower–moderate and CC-0/1 looks achievable, CRS is more meaningful to discuss. Very high burden, diffuse small-bowel “matting,” or unresectable disease usually argues against a maximal operation. There is no single magic PCI threshold for every histology.
- Key note inside
HIPEC is not automatic with CRS
In colorectal peritoneal metastases, oxaliplatin HIPEC did not improve overall survival in PRODIGE-7 atop quality CRS and systemic therapy. HIPEC remains a separate decision — CRS suitability is not the same as mandatory HIPEC.
- Key note inside
More selective / limited evidence
Gastric cancer with peritoneal metastases remains highly selective and controversial; only very chosen cases at experienced centers are discussed. No miracle framing.
General fitness themes
Adequate performance status, controllable systemic disease, acceptable comorbidity, and a realistic chance of complete cytoreduction.
- Performance status adequate
- No uncontrolled distant disease (selected extra-peritoneal exceptions go to the tumor board)
- CC-0/CC-1 appears achievable
- PCI and histology fit the center protocol discussion range
- Key note inside
Important
This page is for education. It is not medical advice and does not replace a visit with your physician.
Frequently asked questions
Who is typically discussed for CRS/HIPEC?
Selected patients with peritoneal disease where complete cytoreduction appears achievable and fitness allows major surgery — often selected colorectal, appendiceal mucinous/PMP, some ovarian, and some mesothelioma pathways.
How do PCI and CC affect eligibility?
PCI estimates burden before/during surgery; CC describes residual disease after CRS. Lower–moderate burden with a realistic CC-0/1 chance supports discussion; very high unresectable burden usually does not. Cut-offs are not identical for every tumor type.
Is colorectal peritoneal disease always offered HIPEC?
No. Evidence boundaries (including oxaliplatin HIPEC debates) should be explained openly.
What imaging is needed?
High-quality cross-sectional staging and surgical assessment of resectability — sometimes with staging laparoscopy.
More chapters in this hub
Appointment / info
This page is for education. It is not medical advice and does not replace a visit with your physician.
Medical editor: Assoc. Prof. Cengiz Dibekoğlu, MD · Last medically reviewed: August 2026 · English patient-education chapter.